Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma

Journal of Immunotherapy

Volumn 33, Issue 8, 2010, Pages 743-758

  Vogel, Thorsten U ^a   Visan, Lucian ^a   Ljutic, Belma ^a   Gajewska, Beata ^a   Caterini, Judy ^a   Salha, Danielle ^a   Wen, Tao ^a   He, Liwei ^a   Parrington, Mark ^a   Cao, Shi Xian ^a   McNeil, Bryan ^a   Sandhu, Devender ^a   Scollard, Nancy ^a   Zhang, Linong ^a   Bradley, Bill ^a   Tang, Mei ^a   Lovitt, Corey ^a   Oomen, Ray ^a   Dunn, Pamela ^a   Tartaglia, Jim ^a   Berinstein, Neil L ^a,b   more..

^a Sanofi Pasteur   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

ALVAC(2); cancer vaccines; melanoma; T cells; TRICOM

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA VACCINE; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; IMMUNOGENICITY; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CANCER VACCINES; CELLS, CULTURED; CLONING, MOLECULAR; CYTOTOXICITY, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; POXVIRIDAE; POXVIRIDAE INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 77958026859     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181eccc87     Document Type: Article

References (71)

1. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer. 1993;54:177-180. (Pubitemid 23154877)
2. Rosenberg SA. A new era of cancer immunotherapy: converting theory to performance. CA Cancer J Clin. 1999;49:70-73.
3. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009;19:275-282.
4. Saleh F, Renno W, Klepacek I, et al. Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anti-cancer vaccine. Curr Pharm Des. 2005;11:3531-3543.
5. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77: 1303-1310.
6. Legha SS, Ring S, Eton O, et al. Development of a bio-chemotherapy regimen with concurrent administration of cispla-tin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752-1759.
7. Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14:2083-2090.
8. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23: 2346-2357.
9. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol. 1999;17:332-337.
10. Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol. 1995;58:1-13.
11. Tartaglia J, Benson J, Cornet B, et al. Potential improvements for poxvirus-based immunization vehicles. In: Girard M, Dodet B, eds. Onzieme Colloque des Cent Gardes. Paris, France: Pasteur Merieux, Marnes-La Coquette; 1997:187-197.
12. Tartaglia J, Jarrett O, Neil JC, et al. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol. 1993;67:2370-2375.
13. Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine. 1988;6:466-468.
14. Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev Biol Stand. 1994;82:65-69.
15. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995; 13:539-549.
16. Spaner DE, Astsaturov I, Vogel T, et al. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer. 2006;106:890-899.
17. Kaufman HL, Lenz HJ, Marshall J, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. 2008;14: 4843-4849.
18. Garnett CT, Greiner JW, Tsang KY, et al. TRICOM vector based cancer vaccines. Curr Pharm Des. 2006;12:351-361.
19. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000;86:385-392.
20. Reynolds SR, Celis E, Sette A, et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol. 1998;161:6970-6976.
21. Reynolds SR, Celis E, Sette A, et al. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J Immunol Methods. 2000;244:59-67.
22. Reynolds SR, Oratz R, Shapiro RL, et al. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer. 1997;72:972-976.
23. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451-6458.
24. Karanikas V, Lurquin C, Colau D, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol. 2003;171:4898-4904.
25. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000;165:948-955.
26. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157:2539-2548.
27. Monsurro V, Nagorsen D, Wang E, et al. Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol. 2002;168:5933-5942.
28. Yang S, Linette GP, Longerich S, et al. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol. 2002;169:531-539.
29. Hodge JW, Grosenbach DW, Rad AN, et al. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine. 2001;19:3552-3567.
30. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999;59:5800-5807.
31. Shankar P, Schlom J, Hodge JW. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Vaccine. 2001;20:744-755.
32. Zhu M, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 2001;61:3725-3734.
33. Grosenbach DW, Barrientos JC, Schlom J, et al. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 2001;61:4497-4505.
34. Hunt DF, Michel H, Dickinson TA, et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science. 1992;256: 1817-1820.
35. Borenstein SH, Graham J, Zhang XL, et al. CD8+ T cells are necessary for recognition of allelic, but not locus-mismatched or xeno-, HLA class I transplantation antigens. J Immunol. 2000;165:2341-2353.
36. Hu N, D'Souza C, Cheung H, et al. Highly conserved pattern of recognition of influenza A wild-type and variant CD8+ CTL epitopes in HLA-A2+ humans and transgenic HLA-A2+/H2 class I-deficient mice. Vaccine. 2005;23:5231-5244.
37. Cadoz M, Strady A, Meignier B, et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 1992; 339:1429-1432.
38. Fang ZY, Limbach K, Tartaglia J, et al. Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. Virology. 2001;291: 272-284.
39. Van Baren N, Bonnet MC, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol. 2005;23:9008-9021.
40. Astsaturov I, Petrella T, Bagriacik EU, et al. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res. 2003;9:4347-4355.
41. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques. 1997;23:1094-1097.
42. Perkus ME, Limbach K, Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol. 1989;63:3829-3836.
43. Schmitt JF, Stunnenberg HG. Sequence and transcriptional analysis of the vaccinia virus HindIII I fragment. J Virol. 1988;62:1889-1897.
44. Smith KA, Stallard V, Roos JM, et al. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences. Vaccine. 1993;11:43-53.
45. Tine JA, Lanar DE, Smith DM, et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun. 1996;64: 3833-3844.
46. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233-240.
47. Hodge JW, Grosenbach DW, Aarts WM, et al. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res. 2003;9:1837-1849.
48. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol. 2005;23:720-731.
49. Zhai Y, Yang JC, Spiess P, et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. 1997; 20:15-25.
50. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci \USA. 1994;91:2105-2109.
51. Gaugler B, Van den EB, van der BP, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994;179: 921-930.
52. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265-270.
53. Jager E, Ringhoffer M, Arand M, et al. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res. 1996;6:419-425.
54. Kawakami Y, Dang N, Wang X, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother. 2000;23:17-27.
55. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180:347-352. (Pubitemid 24181083)
56. Spagnoli GC, Schaefer C, Willimann TE, et al. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosi-nase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer. 1995;64:309-315.
57. Traversari C, Van der BP, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992;176:1453-1457.
58. Firat H, Garcia-Pons F, Tourdot S, et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol. 1999;29:3112-3121.
59. Firat H, Cochet M, Rohrlich PS, et al. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int Immunol. 2002;14:925-934.
60. Men Y, Miconnet I, Valmori D, et al. Assessment of immuno-genicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J Immunol. 1999;162:3566-3573.
61. Liao YP, Wang CC, Butterfield LH, et al. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol. 2004;173: 2462-2469.
62. Valmori D, Levy F, Miconnet I, et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol. 2000;164:1125-1131.
63. Cheuk E, D'Souza C, Hu N, et al. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes. J Immunol. 2002;169:5571-5580.
64. Pascolo S, Bervas N, Ure JM, et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 1997;185:2043-2051.
65. Ramage JM, Metheringham R, Moss R, et al. Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice. Vaccine. 2004;22:1728-1731.
66. Street MD, Doan T, Herd KA, et al. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillo-mavirus type 16 E7 protein. Immunology. 2002;106:526-536.
67. Palmowski MJ, Choi EM, Hermans IF, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol. 2002;168:4391-4398.
68. Rosenberg SA, Sherry RM, Morton KE, et al. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother. 2006;29:224-231.
69. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carci-noembryonic antigen immune responses. J Clin Oncol. 2000;18:3964-3973.
70. Kaufman HL, Cohen S, Cheung K, et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther. 2006; 17:239-244.
71. Kaufman HL, DeRaffele G, Mitcham J, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest. 2005;115: 1903-1912.